Quick Answer
Aura Biosciences, Inc. reported Cash and Equivalents of $59.52 million for fiscal year 2025.
Aura Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $59.52M | +87.8% |
| 2024 | $31.69M | -22.8% |
| 2023 | $41.06M | -66.2% |
| 2022 | $121.58M | -18.4% |
| 2021 | $149.06M | +757.0% |
| 2020 | $17.39M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $47.55M | +87.2% | -55.7% |
| June 30, 2025 | $107.37M | +257.0% | +180.9% |
| March 31, 2025 | $38.23M | +45.5% | +20.6% |
| December 31, 2024 | $31.69M | -22.8% | +24.7% |
| September 30, 2024 | $25.41M | -54.3% | -15.5% |
| June 30, 2024 | $30.07M | -37.0% | +14.4% |
| March 31, 2024 | $26.28M | -31.7% | -36.0% |
| December 31, 2023 | $41.06M | -66.2% | -26.1% |
- Aura Biosciences, Inc. showed an increase of +87.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Aura Biosciences, Inc.’s cash and equivalents has grown by 242.2% (from $17.39 million to $59.52 million).
- The most recent figure is from Aura Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: